Axoltis Pharma
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15 17 Rue Du Pré La Reine, Clermont-Ferr...Phone Number
+33 472621736Website
www.axoltis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Axoltis Pharma
Axoltis Pharma, a French biopharma company, develops innovative drugs for neurodegenerative and neurotraumatic diseases with a high unmet medical need. Headquartered in Clermont-Ferrand with offices in Lyon, France, Axoltis has established several partnerships with internationally recognized academic and private labs to develop its lead product, NX210c. The team is highly experienced in drug development, especially for neurological applications.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Axoltis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Axoltis Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Axoltis Pharma has new funding data
Earning: See what the market has to say on Axoltis Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Axoltis Pharma
Check if Axoltis Pharma has recently received funding, and reach out quickly before it becomes old news!
Axoltis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Axoltis Pharma launches new products
Check out if Axoltis Pharma is spiking on competitors!
Recommended Actions
Find VP level buyers at Axoltis Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Axoltis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Axoltis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Axoltis Pharma.
Axoltis Pharma financials insights
Gather financial insights about Axoltis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$20.9M
Axoltis Pharma Tech Stack
A closer look at the technologies used by Axoltis Pharma
See more technologies
Axoltis Pharma News & Media
Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral ...
Clermont-Ferrand, France, December 2, 2025 – Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new a...InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders
MILAN, July 27, 2023 /PRNewswire/ -- InSilicoTrials, a leading provider of artificial intelligence (AI) and simulation tools for drug and medical device development, has embarked on a collaborative partnership with Axoltis Pharma, a biopharmaceutical company committed to developing...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Axoltis Pharma
Sign Up For FreeTo access detailed company insights
Axoltis Pharma, a French biopharma company, develops innovative drugs for neurodegenerative and neurotraumatic diseases with a high unmet medical need. Headquartered in Clermont-Ferrand with offices in Lyon, France, Axoltis has established several partnerships with internationally recognized academic and private labs to develop its lead product, NX... Read More
